Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial.
幼童患者接受 Eculizumab 治療與安全性:一項針對與席加毒素相關的溶血性尿毒症候群的隨機、安慰劑對照試驗。
J Am Soc Nephrol 2023-10-18
Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement.
Eculizumab在STEC-HUS中的應用:改變兒童患者神經系統參與管理的典範。
Pediatr Nephrol 2023-11-30
Kidney sequelae in 281 Shiga toxin-producing Escherichia coli-hemolytic uremic syndrome patients after a median follow-up of 12 years.
281名Shiga toxin-producing Escherichia coli溶血性尿毒症候群患者12年中位追蹤後的腎臟後遺症。
Pediatr Nephrol 2024-02-28
Gastrointestinal involvement in STEC-associated hemolytic uremic syndrome: 10 years in a pediatric center.
小腸出血性大腸桿菌相關溶血性尿毒症候群的胃腸道參與:一家兒科中心的10年經驗。
Pediatr Nephrol 2024-01-08
Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up.
Shiga toxin-producing E. coli (STEC)相關溶血性尿毒症候群之後10年的結果:長期追蹤的重要性。
Pediatr Nephrol 2024-04-08
Dynamic evolution of kidney function in patients with STEC-hemolytic uremic syndrome followed for more than 15 years: unexpected changes.
STEC-溶血性尿毒症患者15年以上隨訪中腎功能的動態演變:意外變化。
Pediatr Nephrol 2024-04-11